The AML Multiplex Advance Panel provides an extensive genetic evaluation for Acute Myeloid Leukemia using advanced multiplex molecular technologies. Metropolis Healthcare analyses multiple leukemia-associated mutations in a single test to support accurate diagnosis, prognosis, and personalised treatment planning.
Price:
Rs. 14,000.00
Sample Type: EDTA Whole Blood
Fasting Not Requierd
Frequently Asked Questions (FAQ's):
What does the AML Multiplex Advance Panel include at Metropolis Healthcare?
It covers a wide range of AML-related gene mutations assessed together through multiplex molecular testing for comprehensive profiling.
How does Metropolis Healthcare perform this advanced AML panel?
State-of-the-art multiplex PCR and sequencing platforms are used to detect multiple gene alterations simultaneously with high precision.
Who should undergo the AML Multiplex Advance Panel at Metropolis Healthcare?
Patients newly diagnosed with AML or those requiring detailed molecular profiling for treatment planning should consider this panel.
Why is multiplex testing beneficial for AML?
It allows simultaneous evaluation of multiple mutations, improving diagnostic accuracy and reducing the time needed for complete genetic assessment.
How do the results help clinicians?
The panel provides insights into prognosis, therapeutic targets, and personalised treatment strategies based on specific mutations.
Is any special preparation required?
No preparation is needed; a blood or bone marrow sample as advised by the oncologist is sufficient.
How soon are results available from Metropolis Healthcare?
Turnaround time is typically within several working days, depending on the number of markers evaluated.
Are the results reliable?
Yes. Metropolis Healthcare uses validated, quality-controlled multiplex platforms to ensure accurate and clinically meaningful outcomes.